0001209191-18-004062.txt : 20180117 0001209191-18-004062.hdr.sgml : 20180117 20180117175830 ACCESSION NUMBER: 0001209191-18-004062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180112 FILED AS OF DATE: 20180117 DATE AS OF CHANGE: 20180117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kennedy Joseph T CENTRAL INDEX KEY: 0001408920 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21392 FILM NUMBER: 18532417 MAIL ADDRESS: STREET 1: C/O TRANSCEPT PHARMACEUTICALS, INC. STREET 2: 1003 W. CUTTING BLVD., SUITE 110 CITY: POINT RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMARIN CORP PLC\UK CENTRAL INDEX KEY: 0000897448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 6699 020 MAIL ADDRESS: STREET 1: FIRST FLOOR, BLOCK 3, THE OVAL, STREET 2: SHELBOURNE ROAD, BALLSBRIDGE CITY: DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC DATE OF NAME CHANGE: 20000201 FORMER COMPANY: FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC DATE OF NAME CHANGE: 19930322 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-12 0 0000897448 AMARIN CORP PLC\UK AMRN 0001408920 Kennedy Joseph T C/O AMARIN PHARMA, INC. 1430 ROUTE 206 BEDMINSTER NJ 07921 0 1 0 0 General Counsel Ordinary Shares 2018-01-12 4 S 0 9587 4.29 D 41519 D Ordinary Shares 2018-01-16 4 S 0 10000 4.13 D 31519 D Ordinary Shares 2018-01-17 4 S 0 31519 4.03 D 0 D Sales made pursuant to a 10b5-1 trading plan dated December 9, 2016. The Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.27 to $4.30, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Ordinary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.10 to $4.315, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Ordinary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.975 to $4.12, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of Ordinary Shares sold at each separate price Please see the section titled "Remarks" below for additional information. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 3,384,394 Ordinary Shares of the Issuer in the form of stock options and Restricted Stock Units granted under the Amarin Corporation plc 2002 Stock Option Plan and the Amarin Corporation plc 2011 Stock Incentive Plan. /s/ Joseph T. Kennedy 2018-01-17